SI2364308T1 - Pirazinske spojine kot inhibitorji fosfodiesteraze 10 - Google Patents
Pirazinske spojine kot inhibitorji fosfodiesteraze 10Info
- Publication number
- SI2364308T1 SI2364308T1 SI200930429T SI200930429T SI2364308T1 SI 2364308 T1 SI2364308 T1 SI 2364308T1 SI 200930429 T SI200930429 T SI 200930429T SI 200930429 T SI200930429 T SI 200930429T SI 2364308 T1 SI2364308 T1 SI 2364308T1
- Authority
- SI
- Slovenia
- Prior art keywords
- phosphodiesterase
- inhibitors
- pyrazine compounds
- pyrazine
- compounds
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003216 pyrazines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11456708P | 2008-11-14 | 2008-11-14 | |
| US16621209P | 2009-04-02 | 2009-04-02 | |
| PCT/US2009/064637 WO2010057121A1 (en) | 2008-11-14 | 2009-11-16 | Pyrazine compounds as phosphodiesterase 10 inhibitors |
| EP09752705A EP2364308B1 (en) | 2008-11-14 | 2009-11-16 | Pyrazine compounds as phosphodiesterase 10 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2364308T1 true SI2364308T1 (sl) | 2013-01-31 |
Family
ID=41478512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200930429T SI2364308T1 (sl) | 2008-11-14 | 2009-11-16 | Pirazinske spojine kot inhibitorji fosfodiesteraze 10 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US8053438B2 (enExample) |
| EP (1) | EP2364308B1 (enExample) |
| JP (1) | JP5746972B2 (enExample) |
| KR (1) | KR20110083746A (enExample) |
| CN (1) | CN102300860B (enExample) |
| AR (1) | AR074358A1 (enExample) |
| AU (1) | AU2009313768B2 (enExample) |
| BR (1) | BRPI0922095A2 (enExample) |
| CA (1) | CA2742993C (enExample) |
| CL (1) | CL2011001094A1 (enExample) |
| CO (1) | CO6382157A2 (enExample) |
| CR (1) | CR20110326A (enExample) |
| CY (1) | CY1113680T1 (enExample) |
| DK (1) | DK2364308T3 (enExample) |
| EA (1) | EA019206B1 (enExample) |
| ES (1) | ES2397218T3 (enExample) |
| HR (1) | HRP20130054T1 (enExample) |
| IL (1) | IL212687A0 (enExample) |
| MA (1) | MA32889B1 (enExample) |
| MX (1) | MX2011005100A (enExample) |
| NZ (1) | NZ592508A (enExample) |
| PE (1) | PE20110581A1 (enExample) |
| PL (1) | PL2364308T3 (enExample) |
| PT (1) | PT2364308E (enExample) |
| RS (1) | RS52598B (enExample) |
| SI (1) | SI2364308T1 (enExample) |
| SM (1) | SMT201200061B (enExample) |
| TN (1) | TN2011000221A1 (enExample) |
| TW (1) | TWI396689B (enExample) |
| WO (1) | WO2010057121A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| MX2011006575A (es) * | 2008-12-17 | 2011-10-06 | Amgen Inc | Compuestos de aminopiridina y carboxipiridina como inhibidores de la fosfodiesterasa 10. |
| EP2393360B1 (en) | 2009-02-05 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
| CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
| KR101830447B1 (ko) * | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도 |
| PE20121743A1 (es) | 2010-02-19 | 2012-12-22 | Boehringer Ingelheim Int | Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion |
| TWI546302B (zh) | 2010-06-24 | 2016-08-21 | 武田藥品工業股份有限公司 | 稠合雜環化合物 |
| WO2012018909A1 (en) | 2010-08-04 | 2012-02-09 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| EP2602255B1 (en) | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| WO2012020780A1 (ja) | 2010-08-10 | 2012-02-16 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| MX344521B (es) | 2010-11-19 | 2016-12-19 | Ligand Pharm Inc | Aminas heterociclicas y sus usos. |
| WO2012096929A2 (en) | 2011-01-11 | 2012-07-19 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| EP2687529B1 (en) | 2011-03-16 | 2016-07-13 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| TWI570122B (zh) | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
| CA2922849A1 (en) * | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
| CN102911135B (zh) * | 2012-10-18 | 2016-01-13 | 内蒙古工业大学 | 2-巯基苯并噻唑类衍生物的合成方法 |
| AP2015008579A0 (en) | 2013-02-05 | 2015-07-31 | Purdue Pharma Lp | Tamper resistant pharmaceutical formulations |
| US9464076B2 (en) | 2013-03-15 | 2016-10-11 | Daiichi Sankyo Company, Limited | Benzothiophene derivative |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| KR20160092991A (ko) | 2013-09-27 | 2016-08-05 | 님버스 아이리스 인코포레이티드 | Irak 억제제 및 이의 용도 |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| CN104649882A (zh) * | 2015-02-11 | 2015-05-27 | 南通恒盛精细化工有限公司 | 一种磷酸二酯酶抑制剂的中间体制备工艺 |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| TWI730002B (zh) * | 2015-09-18 | 2021-06-11 | 日商科研製藥股份有限公司 | 聯芳系化合物及含有此化合物之醫藥 |
| CN111615515B (zh) * | 2018-01-19 | 2023-11-24 | 苏州信诺维医药科技股份有限公司 | 杂环化合物、制备方法及其在医药上的应用 |
| CN109020977B (zh) * | 2018-10-26 | 2020-11-13 | 安庆奇创药业有限公司 | 一种Acalabrutinib的制备方法 |
| EP4263751B1 (en) | 2020-12-17 | 2025-08-13 | Merck Patent GmbH | Heteroaromatic isothiocyanates |
| CN113929598A (zh) * | 2021-11-24 | 2022-01-14 | 上海吉奉生物科技有限公司 | 一种（s）-2-叔丁氧羰基氨基-3-（4,4-二氟环己基）丙酸的合成方法 |
| EP4524134A1 (en) * | 2022-05-09 | 2025-03-19 | TYK Medicines Inc. | Polycyclic compound and use thereof |
| CN115894181A (zh) * | 2022-09-30 | 2023-04-04 | 渭南高新区海泰新型电子材料有限责任公司 | 一种环己烯基环己基二氟苯类液晶化合物的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198417A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| PT1635828E (pt) | 2003-04-04 | 2008-07-01 | Lundbeck & Co As H | Derivados de 4-(2-feniloxifenil) piperidina ou de 1,2,3,6-tetrahidropiridina como inibidores da recaptação da serotonina |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| DE10344223A1 (de) * | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| BRPI0511295A (pt) * | 2004-05-18 | 2007-12-04 | Schering Corp | 2-quinolil-oxazóis substituìdos úteis como inibidores de pde4 |
| EP1755611A1 (en) * | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| DE102005016634A1 (de) * | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| CA2615890A1 (en) | 2005-08-02 | 2007-02-08 | Irm Llc | 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors |
| AU2007217750A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| CA2650976A1 (en) * | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| PT2125786E (pt) | 2006-12-21 | 2011-04-21 | Pfizer Prod Inc | Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1hpirazol- 3-il)fenoxi)metil)quinolina |
| AU2008315746A1 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
| CN102203074A (zh) | 2008-06-20 | 2011-09-28 | 麦它波莱克斯股份有限公司 | 芳基gpr119激动剂及其用途 |
-
2009
- 2009-11-13 TW TW098138718A patent/TWI396689B/zh not_active IP Right Cessation
- 2009-11-16 EP EP09752705A patent/EP2364308B1/en active Active
- 2009-11-16 EA EA201100748A patent/EA019206B1/ru not_active IP Right Cessation
- 2009-11-16 PE PE2011001035A patent/PE20110581A1/es not_active Application Discontinuation
- 2009-11-16 BR BRPI0922095A patent/BRPI0922095A2/pt not_active IP Right Cessation
- 2009-11-16 SI SI200930429T patent/SI2364308T1/sl unknown
- 2009-11-16 JP JP2011536567A patent/JP5746972B2/ja not_active Expired - Fee Related
- 2009-11-16 MX MX2011005100A patent/MX2011005100A/es active IP Right Grant
- 2009-11-16 NZ NZ592508A patent/NZ592508A/xx not_active IP Right Cessation
- 2009-11-16 PT PT97527055T patent/PT2364308E/pt unknown
- 2009-11-16 CA CA2742993A patent/CA2742993C/en not_active Expired - Fee Related
- 2009-11-16 WO PCT/US2009/064637 patent/WO2010057121A1/en not_active Ceased
- 2009-11-16 HR HRP20130054AT patent/HRP20130054T1/hr unknown
- 2009-11-16 RS RS20120569A patent/RS52598B/sr unknown
- 2009-11-16 KR KR1020117013506A patent/KR20110083746A/ko not_active Withdrawn
- 2009-11-16 US US12/619,574 patent/US8053438B2/en not_active Expired - Fee Related
- 2009-11-16 CN CN200980154871.6A patent/CN102300860B/zh not_active Expired - Fee Related
- 2009-11-16 PL PL09752705T patent/PL2364308T3/pl unknown
- 2009-11-16 DK DK09752705.5T patent/DK2364308T3/da active
- 2009-11-16 AU AU2009313768A patent/AU2009313768B2/en not_active Ceased
- 2009-11-16 ES ES09752705T patent/ES2397218T3/es active Active
- 2009-11-16 AR ARP090104436A patent/AR074358A1/es not_active Application Discontinuation
-
2011
- 2011-03-07 US US13/042,410 patent/US8329700B2/en not_active Expired - Fee Related
- 2011-03-07 US US13/042,421 patent/US8247418B2/en not_active Expired - Fee Related
- 2011-05-04 IL IL212687A patent/IL212687A0/en unknown
- 2011-05-05 TN TN2011000221A patent/TN2011000221A1/fr unknown
- 2011-05-13 CL CL2011001094A patent/CL2011001094A1/es unknown
- 2011-06-10 MA MA33928A patent/MA32889B1/fr unknown
- 2011-06-14 CR CR20110326A patent/CR20110326A/es not_active Application Discontinuation
- 2011-06-14 CO CO11073978A patent/CO6382157A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/531,453 patent/US20120277209A1/en not_active Abandoned
- 2012-12-19 SM SM201200061T patent/SMT201200061B/it unknown
- 2012-12-21 CY CY20121101246T patent/CY1113680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL212687A0 (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| HUS1700051I1 (hu) | Pirrolopiridin vegyületek, mint CDK inhibitorok | |
| IL200617A0 (en) | Substituted pyrimidodiazepines useful as plk1 inhibitors | |
| GB201000648D0 (en) | Phosphodiesterase 10 inhibitors | |
| ZA201102423B (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| IL201073A0 (en) | Pyrrolopyrimidine derivatives as jak3 inhibitors | |
| ZA201008808B (en) | Novel phenylpyrazinones as kinase inhibitors | |
| IL213464A0 (en) | Kinase inhibitor compounds | |
| IL210573A0 (en) | Compounds as kinase inhibitors | |
| IL194424A0 (en) | 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors | |
| IL206394A0 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| IL200153A0 (en) | Novel phosphodiesterase inhibitors | |
| ZA201008878B (en) | Naphthyridiniones as aurora kinase inhibitors | |
| EP2314587A4 (en) | HETEROCYCLIC NITROGEN COMPOUND | |
| IL210099A0 (en) | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds | |
| ZA200905371B (en) | Novel phosphodiesterase Inhibitors | |
| ZA201104380B (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| EP1998776A4 (en) | MACRO-HETEROCYL COMPOUNDS CONTAINING PYRIDINE AS KINASE INHIBITORS |